YM177 + etodolac + Placebo

Phase 3Completed
1 views this week 0 watching Active
Interest: 40/100
40
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Post Operative Pain

Conditions

Post Operative Pain

Trial Timeline

Feb 1, 2010 → Nov 1, 2010

About YM177 + etodolac + Placebo

YM177 + etodolac + Placebo is a phase 3 stage product being developed by Astellas Pharma for Post Operative Pain. The current trial status is completed. This product is registered under clinical trial identifier NCT01118572. Target conditions include Post Operative Pain.

What happened to similar drugs?

20 of 20 similar drugs in Post Operative Pain were approved

Approved (20) Terminated (1) Active (0)
raloxifene + PlaceboEli LillyApproved
QUTENZAAstellas PharmaApproved
Teriparatide + Zoledronic AcidEli LillyApproved
teriparatideEli LillyApproved
Teriparatide + RaloxifeneEli LillyApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01118572Phase 3Completed

Competing Products

20 competing products in Post Operative Pain

See all competitors
ProductCompanyStageHype Score
PRF110- oily solution (Ropivacaine)PainReformPhase 2
25
PRF110PainReformPhase 2
21
ENZ215 + ProliaAlkem LaboratoriesPhase 3
40
teriparatide + teriparatide + Placebo + Calcium Supplement + Vitamin D SupplementEli LillyPhase 3
40
raloxifene + PlaceboEli LillyApproved
43
MBX 1416 (INN imapextide)MBX BiosciencesPhase 2
36
MBX 1416 (Part A) + MBX 1416 (Part B) + Placebo + MBX 1416 (Part C)MBX BiosciencesPhase 1
23
teriparatide 20 micrograms/day subcutaneous + calcitonin 100 IU/day subcutaneousEli LillyPhase 3
40
teriparatide 20 micrograms/day subcutaneous + salmon calcitonin 100 IU/day subcutaneousEli LillyPhase 3
40
CT-P41 + US-licensed ProliaCelltrionPhase 3
40
LetrozoleChugai PharmaceuticalPhase 2
35
Eldecalcitol soft capsulesChugai PharmaceuticalPre-clinical
22
LetrozoleChugai PharmaceuticalPhase 2
35
LetrozoleChugai PharmaceuticalPhase 2
35
Placebo + DS-5565Daiichi SankyoPre-clinical
26
QUTENZAAstellas PharmaApproved
43
QutenzaAstellas PharmaPre-clinical
26
CelecoxibAstellas PharmaPre-clinical
26
ASP8477 + PlaceboAstellas PharmaPhase 2
35
Naldemedine + PlaceboShionogiPhase 2
27